Biotech projects get associated with pricing scandals---politicians love bashing the industry
Jackson Moses, 10-19-2016, Moses is a venture capitalist and head of partnerships at MainStreet "Biotech Bashing: Pills, Politics, & Endless Potential," No Publication, https://www.linkedin.com/pulse/biotech-bashing-pills-politics-endless-potential-jackson-moses//DG
The Blame Game: How Tit-For-Tat Thinking Is Sinking Biotech Long the ire of Clinton, Warren, Sanders, and (now) Trump, Mylan's EpiPen pricing scandal provided politicians a prime excuse to attack the biotech sector for all healthcare-related problems. After news broke of Mylan's 500% EpiPen price hike, seasoned politicians (Democrat and Republican) took to , bashing the biotech industry for egregious price-gouging practices. As such, in an attempt to curb her impending PR nightmare, Mylan CEO Heather Bresch responded to media accusations by stating annual EpiPen price hikes were justified due to ongoing R&D costs (strike one), discounted public school rates (strike two), and Obamacare's failed incentive structure (strike three). Unsurprisingly, the aforementioned rationale didn't resonate with middle-class voters. The American public had quickly reached a populous conclusion, which also established a dangerous precedent: corporate greed is a punishable offense. The message was clear, if U.S. Representatives wanted to remain employed, Congress would hold "greedy" executives accountable for their private sector "crimes." Rightfully realizing the rare opportunity to acquire significant political capital, Hillary Clinton the following: "EpiPens can be the difference between life and death. There's no justification for these price hikes." She then released an official follow-up statement and demanded "Mylan immediately reduce the price of EpiPens." Market participants responded by dumping Mylan stock to the tune of 10%.